Tema Cardiovascular and Metabolic ETF's Tema Cardiovascular and Metabolic ETF (HRTS) has disclosed 42 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-02-29. The current portfolio value is calculated to be $47.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 66%.
Tema Cardiovascular and Metabolic ETF (HRTS)'s
Total Assets is $49.17 Mil , Total Liabilities is $1.28 Mil , Net Assets is $47.90 Mil.
In Tema Cardiovascular and Metabolic ETF (HRTS)'s current portfolio as of 2024-02-29, the top 5 holdings are
Eli Lilly and Co (LLY), Vertex Pharmaceuticals Inc (VRTX), Novo Nordisk A/S (OCSE:NOVO B), Amgen Inc (AMGN) and Viking Therapeutics Inc (VKTX),
not including call and put options.
Tema Cardiovascular and Metabolic ETF (HRTS) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Tema Cardiovascular and Metabolic ETF (HRTS), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Tema Cardiovascular and Metabolic ETF (HRTS), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Tema Cardiovascular and Metabolic ETF.